Detection of suPAR in the saliva of healthy young adults: Comparison with plasma levels

Biomarker Insights

Volumn 6, Issue , 2011, Pages 119-125

  Gustafsson, Anna ^a   Ajeti, Vjosa ^a   Ljunggren, Lennart ^a  

^a MALMÖ UNIVERSITY   (Sweden)

Author keywords

Plasma suPAR; Saliva biomarkers; Saliva CRP; Saliva suPAR

Indexed keywords

C REACTIVE PROTEIN; UROKINASE RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; C REACTIVE PROTEIN BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SALIVA ANALYSIS; SALIVA LEVEL; UROKINASE RECEPTOR BLOOD LEVEL; UROKINASE RECEPTOR SALIVA LEVEL;

EID: 83455259390     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S8326     Document Type: Article

References (23)

1. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157-72.
2. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-43.
3. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood. 1998;91:2305-12.
4. Rabna P, Andersen A, Wejse C, Oliveira I, Francisco Gomes V, Bonde Haaland M, et al. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Inflammation. 2010;33: 374-80.
5. Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 1998;58:3294-8.
6. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis. 2004;36:14-9.
7. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296-308.
8. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011.
9. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis. 2008;27:375-83.
10. Sehestedt T, Lyngbaek S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis. 2011;216:237-43.
11. Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev. 2011;20:609-18.
12. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis. 2002;6:686-92.
13. Kinnby B, Lindberg P, Lecander I, Matsson L. Localization of plasminogen activators and plasminogen-activator inhibitors in human gingival tissues demonstrated by immunohistochemistry and in situ hybridization. Arch Oral Biol. 1999;44:1027-34.
14. Yin X, Bunn CL, Bartold PM. Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2(PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients. J Clin Periodontol. 2000;27:149-56.
15. Virtanen OJ, Siren V, Multanen J, Farkkila M, Leivo I, Vaheri A, et al. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. Eur J Oral Sci. 2006;114:22-6.
16. Masucci MT, Pedersen N, Blasi F. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem. 1991;266:8655-8.
17. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15:R63.
18. Yilmaz G, Koksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem. 2011.
19. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999;58:488-92.
20. Dillon MC, Opris DC, Kopanczyk R, Lickliter J, Cornwell HN, Bridges EG, et al. Detection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levels. Biomark Insights. 2010;5:57-61.
21. Ouellet-Morin I, Danese A, Williams B, Arseneault L. Validation of a high-sensitivity assay for C-reactive protein in human saliva. Brain Behav Immun. 2011;25:640-6.
22. Punyadeera C, Dimeski G, Kostner K, Beyerlein P, Cooper-White J. Onestep homogeneous C-reactive protein assay for saliva. J Immunol Methods. 2011.
23. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med. 2011;123:114-9.